Mediwound ( (MDWD) ) has released its Q3 earnings. Here is a breakdown of the information Mediwound presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MediWound Ltd., a global biotechnology company, specializes in enzymatic, non-surgical therapies for tissue repair, with its FDA-approved product NexoBrid® for burn treatment and EscharEx® for chronic wound management in late-stage development.
In its third-quarter 2025 earnings report, MediWound highlighted significant progress in its clinical and operational activities, including the ongoing enrollment in the VALUE Phase III trial of EscharEx for venous leg ulcers and the completion of commissioning for an expanded NexoBrid manufacturing facility. The company also strengthened its financial position with a $30 million equity financing.
Financially, MediWound reported a 23% year-over-year increase in revenue, reaching $5.4 million for the third quarter of 2025. The company also noted a reduction in net loss to $2.7 million, driven by non-cash financial income from warrant revaluation. However, operating losses widened due to increased research and development expenses related to the EscharEx trial.
Strategically, the company is poised to meet growing global demand with its expanded production capacity for NexoBrid, which has seen increased adoption in the U.S. and approval for use in Australia. Additionally, the company anticipates initiating a clinical trial for EscharEx in diabetic foot ulcers in 2026, with a peak sales potential estimated at $831 million.
Looking ahead, MediWound remains focused on advancing its late-stage pipeline and driving revenue growth, supported by its strengthened balance sheet and expanded operational capabilities. The company aims to deliver long-term value through continued innovation and market expansion.